AbbVie Inc. Stock 12‑Month Price Target Raised to $291

What happened

Estimates from 26 analysts put AbbVie Inc.’s average 12-month share price target at $291, up from $289.08. Their forecasts range from $230 to $350 per share. The consensus rating remains “Buy,” with 24 Buys, 7 Holds, and 1 Sell among 32 covering analysts.

Confirmed

Global impact / market context

A higher average target indicates analysts, in aggregate, now estimate a higher share value over the next 12 months. If investors act on that view, demand for AbbVie shares could rise, though the target is an estimate, not a guaranteed outcome or a company earnings forecast.

Analyst inference

The unchanged “Buy” consensus alongside a slightly higher average target suggests the update is a revision in expected share value rather than a reported change in AbbVie’s business. The broad forecast range shows analysts differ substantially about where the shares may trade.

Analyst inference

What to watch

1. Watch for subsequent analyst target revisions and rating changes: further upward or downward changes would show whether the current estimate is being reinforced or reversed. Analyst inference
2. Compare the share price with the $291 average target and the $230–$350 forecast range; these are analyst estimates, not promises of future performance. Analyst inference
3. The reported consensus covers 32 analysts, while the average target uses estimates from 26; changes in those counts could affect how representative each figure is. Confirmed

Evidence

• Original source link unavailable